These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 33629745)

  • 21. Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Wang Z; Chen Y; Lin Y; Wang X; Cui X; Zhang Z; Xian G; Qin C
    Int J Oncol; 2017 Oct; 51(4):1239-1248. PubMed ID: 28849150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
    Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway.
    Yu C; Chen S; Guo Y; Sun C
    Theranostics; 2018; 8(12):3224-3236. PubMed ID: 29930725
    [No Abstract]   [Full Text] [Related]  

  • 24. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution.
    Le Calvé B; Griveau A; Vindrieux D; Maréchal R; Wiel C; Svrcek M; Gout J; Azzi L; Payen L; Cros J; de la Fouchardière C; Dubus P; Guitton J; Bartholin L; Bachet JB; Bernard D
    Oncotarget; 2016 May; 7(22):32100-12. PubMed ID: 27050073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal.
    Pan Y; Li K; Tao X; Zhao Y; Chen Q; Li N; Liu J; Go VLW; Guo J; Gao G; Xiao GG
    Pancreas; 2021 Oct; 50(9):1260-1266. PubMed ID: 34860809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ARID3A enhances chemoresistance of pancreatic cancer via inhibiting PTEN-induced ferroptosis.
    Mao X; Xu J; Xiao M; Liang C; Hua J; Liu J; Wang W; Yu X; Meng Q; Shi S
    Redox Biol; 2024 Jul; 73():103200. PubMed ID: 38781729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
    Zhang L; Yao J; Li W; Zhang C
    Oncol Res; 2018 Jul; 26(6):827-835. PubMed ID: 28477403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
    Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
    Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
    Ju HQ; Li H; Tian T; Lu YX; Bai L; Chen LZ; Sheng H; Mo HY; Zeng JB; Deng W; Chiao PJ; Xu RH
    J Pineal Res; 2016 Jan; 60(1):27-38. PubMed ID: 26445000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
    Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H
    Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance.
    Ma MJ; Shi YH; Liu ZD; Zhu YQ; Zhao GY; Ye JY; Li FX; Huang XT; Wang XY; Wang JQ; Xu QC; Yin XY
    Oncogene; 2024 Jul; 43(31):2405-2420. PubMed ID: 38914663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
    Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
    J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrin β1 promotes gemcitabine resistance in pancreatic cancer through Cdc42 activation of PI3K p110β signaling.
    Yang D; Tang Y; Fu H; Xu J; Hu Z; Zhang Y; Cai Q
    Biochem Biophys Res Commun; 2018 Oct; 505(1):215-221. PubMed ID: 30243721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.
    Cai B; An Y; Lv N; Chen J; Tu M; Sun J; Wu P; Wei J; Jiang K; Miao Y
    Oncol Rep; 2013 May; 29(5):1769-76. PubMed ID: 23440261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gemcitabine Enhances Kras-MEK-Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells.
    Shimizu K; Nishiyama T; Hori Y
    Pancreas; 2017 Feb; 46(2):268-275. PubMed ID: 28060183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Palam LR; Gore J; Craven KE; Wilson JL; Korc M
    Cell Death Dis; 2015 Oct; 6(10):e1913. PubMed ID: 26469962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FAM84B, amplified in pancreatic ductal adenocarcinoma, promotes tumorigenesis through the Wnt/β-catenin pathway.
    Zhang X; Xu J; Yan R; Zhang Y; Hu Z; Fu H; You Q; Cai Q; Yang D
    Aging (Albany NY); 2020 Apr; 12(8):6808-6822. PubMed ID: 32291380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine.
    Miller AL; Fehling SC; Vance RB; Chen D; Brown EJ; Hossain MI; Heard EO; Andrabi SA; Wang H; Yang ES; Buchsbaum DJ; van Waardenburg RCAM; Bellis SL; Yoon KJ
    Cancer Lett; 2024 Jun; 592():216919. PubMed ID: 38704133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth Hormone Receptor Antagonist Markedly Improves Gemcitabine Response in a Mouse Xenograft Model of Human Pancreatic Cancer.
    Basu R; Kulkarni P; Swegan D; Duran-Ortiz S; Ahmad A; Caggiano LJ; Davis E; Walsh C; Brenya E; Koshal A; Brody R; Sandbhor U; Neggers SJCMM; Kopchick JJ
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Skeletal Muscle-Derived Irisin Enhances Gemcitabine Sensitivity and Suppresses Migration Ability in Pancreatic Ductal Adenocarcinoma.
    Sugimoto T; Iwagami Y; Kobayashi S; Yamanaka C; Sasaki K; Yamada D; Tomimaru Y; Asaoka T; Noda T; Takahashi H; Shimizu J; Doki Y; Eguchi H
    Ann Surg Oncol; 2024 Jun; 31(6):3718-3736. PubMed ID: 38502294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.